Holen Sie sich die Stockscreener-App
11.10
2.29%
-0.26
Schlusskurs vom Vortag:
$11.36
Offen:
$11.23
24-Stunden-Volumen:
3.08M
Relative Volume:
2.40
Marktkapitalisierung:
$1.44B
Einnahmen:
$8.40M
Nettoeinkommen (Verlust:
$-237.42M
KGV:
-5.7773
EPS:
-1.9213
Netto-Cashflow:
$-377.03M
1W Leistung:
-50.40%
1M Leistung:
-59.07%
6M Leistung:
-61.55%
1J Leistung:
+141.30%
1-Tages-Spanne:
$11.01
$11.60
1-Wochen-Bereich:
$8.75
$22.55
52-Wochen-Spanne:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
11.10 | 2.96B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (NASDAQ:ALMS) Shares Down 7.9%What's Next? - MarketBeat
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders - simplywall.st
Equities Analysts Set Expectations for Alumis Q3 Earnings - MarketBeat
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target - Investing.com
Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder - Stock Titan
Alumis (NASDAQ:ALMS) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Alumis' (ALMS) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss - MarketBeat
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Slightly Overshadows Share DeclineLong-Term Guidance - Vinanet
Alumis Swings to Q2 Net Loss, Revenue Falls - marketscreener.com
ALMS SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Alumis (NASDAQ:ALMS) Issues Earnings Results - marketbeat.com
Alumis Q2 Results: EPS Misses Estimate, Sales Fall 37% YoY - scanx.trade
Alumis (ALMS) Posts Q2 Loss; Price-to-Sales Ratio Highlights Mar - GuruFocus
Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash - Stock Titan
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements - The Manila Times
Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, vs. FactSet Est of $3.5M - marketscreener.com
Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, Vs. FactSet Est of $3.5M - Moomoo
California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS - MarketBeat
Alumis Inc. (ALMS) Climbs 1.69% as Biotech Stock Approaches Key Resistance at $27.09Value Area High - vinanet.vn
Alumis (NASDAQ:ALMS) Trading Down 9.6%Should You Sell? - MarketBeat
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 - The Globe and Mail
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates - Benzinga
Alumis reports 54% complete skin clearance in psoriasis trial By Investing.com - Investing.com South Africa
Alumis reports 54% complete skin clearance in psoriasis trial - Investing.com
Alumis: Envudeucitinib Shows 54% PASI 100 at 48 Weeks, NDA on Track for 4Q 2026 - TradingView
First Trust Advisors LP Takes $1.46 Million Position in Alumis Inc. $ALMS - MarketBeat
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc. $ALMS Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Technical Reactions to ALMS Trends in Macro Strategies - Stock Traders Daily
FMR reports 5.5% Alumis Inc (ALMS) stake in Schedule 13G filing - stocktitan.net
Bank of New York Mellon Corp Raises Holdings in Alumis Inc. $ALMS - MarketBeat
Alumis (NASDAQ:ALMS) Insider Jorn Drappa Sells 2,447 Shares of Stock - MarketBeat
Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 1,364 Shares of Stock - MarketBeat
Alumis (NASDAQ:ALMS) CFO John Schroer Sells 3,282 Shares - MarketBeat
Alumis (ALMS) CFO sells 3,282 shares in tax-related sell-to-cover trade - Stock Titan
Alumis Inc. (ALMS) officer sells 2,692 shares in tax sell-to-cover trade - Stock Titan
Alumis Inc. (ALMS) CDO sells 2,572 shares to cover RSU taxes - stocktitan.net
Alumis (ALMS) to Post Quarterly Earnings on Wednesday - MarketBeat
Alumis (NASDAQ:ALMS) Given Neutral Rating at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Trading Down 4.1%Should You Sell? - MarketBeat
Janus Henderson Group PLC Takes $46.79 Million Position in Alumis Inc. $ALMS - MarketBeat
Swiss National Bank Takes $2.81 Million Position in Alumis Inc. $ALMS - MarketBeat
Stempoint Capital LP Buys New Stake in Alumis Inc. $ALMS - MarketBeat
166,959 Shares in Alumis Inc. $ALMS Purchased by Ally Bridge Group NY LLC - MarketBeat
Elmind Capital LP Purchases New Shares in Alumis Inc. $ALMS - MarketBeat
BlackRock, Inc. (ALMS) reports 7.1M-share, 5.7% beneficial stake in Alumis - Stock Titan
Alumis Market Sentiment - Benzinga España
ALMS|Alumis Inc|Price:27.070|Chg%:-0.930 - TradingKey
Orbimed Advisors LLC Has $12.08 Million Stock Holdings in Alumis Inc. $ALMS - MarketBeat
ALMS|Alumis Inc|Price:26.312|Chg%:-0.768 - TradingKey
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Sale |
28.00 |
5,000 |
140,000 |
11,111 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):